Wire open Last filed GLP 1 allodynia reports link weight loss drugs to burning skin pain RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire

Peptide medicine news filed as it happens

Peptide Zone is a news wire for peptide medicines such as GLP-1 drugs, amylin analogues and peptide vaccines. Each story covers one regulator decision, trial readout, industry deal or safety review, names its primary source and says what comes next. Nothing here is medical advice. About the newsroom

RoutineSAFNews

GLP 1 allodynia reports link weight loss drugs to burning skin pain

Case reports and patient accounts describe skin that burns at a light touch on semaglutide and tirzepatide. Trials count a broader symptom, dysesthesia, more often with experimental retatrutide, but no study shows cause or frequency.

BOSTON

20.9%Share reporting dysesthesia on the higher retatrutide dose in Phase 3 data, against 0.7% on placebo, per the Daily Mail
  1. What's newThe Daily Mail reported patient accounts and published case reports of allodynia, skin that hurts at a light touch, in people taking semaglutide or tirzepatide. Several patients improved after a dose cut or a pause.
  2. Why it mattersAllodynia is not a listed side effect of these drugs, and trials count only the broader symptom dysesthesia, which appears more often with experimental retatrutide at a higher dose.
  3. What's nextResearchers have not established how often the symptom occurs or who is at risk. Trials that report allodynia separately and wider case collection would be needed to test a link.

Latest on the wire

Full wire

The 60-second briefing

Five things filed most recently

  1. TRL · 5 Nov 2026Camurus dosed the first patient in LUNAR-2, a placebo-controlled Phase 2b trial of its monthly semaglutide depot CAM2056 in 150 adults with obesity or overweight.
  2. TRL · 5 Nov 2026A post hoc VALIANT and VALE analysis presented at Kidney Week 2026 found 53 adolescents with C3G or primary IC-MPGN kept a 67.5% proteinuria reduction at 76 weeks on pegcetacoplan, with stable eGFR and no new safety signals.
  3. IND · 5 Nov 2026Novo Nordisk said its Wegovy pill took about 80% of new US prescriptions in its class in Q3 and raised its 2026 adjusted sales and operating profit outlook to between minus 2% and plus 2% at CER.
  4. SAF · 5 Nov 2026Three GPs quoted in a Daily Mail column advised people on weight loss jabs not to raise or skip doses for the Christmas party season. One said ad hoc changes are unlikely to be dangerous but are not the recommended route.
  5. SAF · 4 Nov 2026A UK GP urged Mounjaro and Wegovy users to put used needles in sharps bins, after the BBC reported needles and sharps containers turning up at a Coventry recycling plant.

By the numbers

The one figure each story turns on.

20.9% vs 9.4%Average weight loss at 80 weeks on the higher retatrutide dose versus Ozempic, per Lilly TRL · 28 OCT · Retatrutide Ozempic trial shows bigger A1C drop and double the weight loss 28.7%average weight loss on the highest dose after 68 weeks TRL · 11 DEC · Retatrutide posts the largest average weight loss yet in a phase 3 trial 62.9%of treated patients saw liver inflammation resolve without fibrosis worsening, vs 34.3% on placebo REG · 15 AUG · Wegovy gets accelerated approval for fatty liver disease with scarring 20.2%average weight loss on tirzepatide vs 13.7% on semaglutide after 72 weeks TRL · 11 MAY · Tirzepatide beats semaglutide on weight loss head to head 1stprescription drug approved to treat obstructive sleep apnea in adults with obesity REG · 20 DEC · FDA clears tirzepatide as the first medicine for obstructive sleep apnea 4 adsPrescription only weight loss pill ads from Voy, Juniper and MedExpress banned by the ASA REG · 04 NOV · UK watchdog bans four weight loss pill ads that never named the drug

Threads we are following

Storylines that span months. Each dot is a story, placed by date.

Thread · 4 stories

Compounded copies and the rules around them

What can people legally get, and how do regulators react when demand outruns supply?

Dec 2024Nov 2026

  • 21 MARSemaglutide copies arrive as key patents lapse outside the US and Europe
  • 06 JUNEU safety committee adds a rare eye condition to semaglutide warnings

Thread · 6 stories

The incretin race

Who ends up with the most weight loss, the fewest side effects and the easiest dosing?

Dec 2024Nov 2026

  • 22 DECThe first GLP 1 pill for weight management gets the green light
  • 07 AUGThe weight loss pill that is not a peptide posts its first obesity readout

Thread · 4 stories

Beyond the scale

Which organ benefits hold up in outcome trials, and which do not?

Dec 2024Nov 2026

  • 24 NOVWhy semaglutide failed to slow Alzheimer's in the EVOKE trials
  • 28 JANSemaglutide wins a kidney label after the FLOW outcome trial

Desk fronts

REGRegulators11
TRLTrials24
INDIndustry16
SAFSafety24
EXPExplainers4

Where this news came from

Primary source type of every story on the wire. How we label sources

  • Regulator15
  • Journal10
  • Company release21
  • Conference8
  • Our newsroom25